Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Science diplomacy ensures equitable healthcare

Lisette Pérez Ojeda 2019. Head, International Affair Office at the Center for State Control of Drugs and Medical Devices (CECMED), Cuba. She has a Masters in Clinical Pharmacy. “Science Diplomacy for Strengthening Medicine Regulatory Systems in The Americas: Emerging Regional Experience” In SCIENCE DIPLOMACY REVIEW, Vol. 1 | No. 3 | July 2019, https://www.ris.org.in/sites/default/files/2021-09/SDR%20July%202019%203-min.pdf IZP)

Introduction Science diplomacy is the use of scientific collaborations among nations to address common problems facing 21st century humanity and in building constructive international partnerships (Fedoroff, 2009). This applies also in the field of health regulations and regulatory science. Good Health and Well Being is Goal 3 of the Sustainable Development Goals. Its aim is to achieve universal health coverage and provide access to safe and affordable medicines and vaccines to all (United Nations, 2015a). Supporting research and development for vaccines is an essential part of this process as well (United Nations, 2015b). Regulatory systems play a key role in assuring quality, safety and efficacy of medical products. An effective regulatory system is an essential component of the health system, and it contributes to desired public health outcomes and innovation. National Regulatory Authorities (NRAs) are government entities responsible for ensuring safety, efficacy and quality of medicines; and they play a vital role in the health- care system by providing regulatory oversight of all medical products. Since many decades, a growing number of networks and initiatives have been developed to strengthen medicines regulatory systems. The region of the Americas has developed an initiative to strengthen health regulatory systems through an evaluation- and- certification process that allows appointment of Regional Reference Regulatory Authorities of medicines and biological products (NRArs). NRArs work jointly through cooperation mechanism on capacity- building in other countries of the region; allowing them to strengthen their regulatory systems and act as a group with consensual positions in different international forums (Ojeda, 2016). Strengthening Regulatory Systems in the Americas National Regulatory Authorities play a vital role in the health- care system by providing regulatory oversight of all medical products such as medicines, vaccines, blood products, traditional or herbal medicines and medical devices. They perform their mandate based on a legal framework along with a set of recommended regulatory functions that span the medical product life- cycle, including clinical trial oversight, marketing authorization and registration, licensing and inspection of premises, market surveillance and enforcement activities when required. The Americas is a region of deep asymmetries where inequalities to access have persisted in poor and vulnerable populations, and there still exists fragmentation and segmentation in the system, which should guarantee access to health technologies. In the case of national regulatory authorities, large difference in structure and autonomy of the regulatory bodies, financing systems and their regulatory capacity are abridged to ensure effective compliance with their functions (Ojeda, 2016). In the last two decades, a group of global and regional initiatives have been developed for strengthening NRAs’ capacities, based on the population’s right to access to quality medicines commensurate with science and technology advances. One of the initiatives is the evaluation and certification of the Regional Reference Regulatory Authorities’ process in the Americas. In 2006, a group of five regulatory authorities from Latin America (Argentina, Brazil, Chile, Cuba and Mexico) had met in Oaxaca, Mexico, with a proposal to build a common agenda to consolidate mutual trust in regulatory matters for the economic well-being and public health of inhabitants of the region.1 That led to the proposal of an NRA evaluation process as the regional mechanism of certification of drugs regulatory authorities, focusing on evaluation of their performance in fulfillment of their functions, and also for serving as the capacity- building mechanism in the regulation of medicinal products’ field. The evaluation process concludes with the rating of the authority assessed, according to its results in one of the four levels. A Regional Reference Authority reaches level IV—this describes an authority that is competent and efficient in fulfilling functions recommended by PAHO/WHO to ensure efficacy, safety and quality of medicines. The Pan American Health Organization (PAHO) acts as the facilitator of the process leading to evaluation and giving certification to the Regional Reference Regulatory Authority for medicinal products and biologists to those very NRAs which reach level IV. To- date, 8 National Regulatory Authorities have been recognized by PAHO/WHO as National Regulatory Authorities of Regional Reference— Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT);Brazil’s National Health Surveillance Agency (ANVISA);the Center for State Control of Drug and Medical Devices of Cuba (CECMED);the National Institute of Food and Drug Monitory of Colombia (INVIMA);the Federal Commission for Protection against Sanitary Risks of the United Mexican States (COFEPRlS);Canada’s Health Canada, US Food and Drug Administration and Chile’s Institute of Public Health (P AHOc, 2018) A significant milestone was the discussion of this initiative at the 50th P AHO Directing Council meeting, in September 2010, and the approval of Resolution CD50. R9: “Strengthening National Regulatory Authorities for Medicines and Biologicals”. In this resolution, P AHO Member States were urged to strengthen and evaluate their regulatory capabilities with respect to the functions characteristic of the regulatory and oversight agency for medicines and biologicals through examination of the performance of their essential functions; to use the results of the qualification activity and the designation of the regulatory authorities of regional reference to strengthen their performance in terms of steering role of the health authority; and to support national regulatory authorities so that they can benefit from the processes and information from the national regulatory authorities of reference (PAHO, 2010) The regional reference authorities work as a network; which together with PAHO are committed to support efforts to strengthen other regulatory agencies, based on their own experience by promoting exchange and cooperation among countries and by actively participating in regulatory harmonization efforts within the framework of the Pan American Network for Drug Regulatory Harmonization (P ANDRH). Considering this, they develop a wide range of cooperation activities for capacity -building in other NRAs. From 2010 till- date, more than 30 courses have been carried out in different countries of the region along with bilateral consultancies and internships in the ARNr2. They also lead different regional projects on pharmaceutical regulation approved by PANDRH (PAHO, 2016). These reference authorities are also working in building trust among themselves while sharing information on their best practices and in exchanging technical information to achieve mutual recognition of their regulatory decisions to speed-up drugs’ approval processes allowing their better access. Regulatory collaboration through inter-agency work and data-sharing help to strengthen the regulatory capacity of all partners by promoting sustainable exchange of technical knowledge. Some bilateral agreements have been established to highlight inspection of final report exchange, considering large number of pharmaceutical companies, and the cost of in situ inspections, to establish mutual recognition of Good Manufacturing Practices Compliance. Regional Reference Authorities in Multilateral Forums In 2011, a group of ARNr was created—this group carries out two annual meetings; in the first semester it reviews the results of the work of the previous year and defines strategies and working plan for the new year3 and in the second semester, a meeting with PAHO is held to evaluate progress of their joint work to strengthen regulatory systems in the region. The following section highlights the regional level initiatives: The Regional Working Group on Medical Device Regulation: Established during the “1st Regional Meeting of the Regulatory Authorities for the Strengthening of Regulatory Capacity on Medical Devices in the Americas Region” held in La Habana, Cuba. It currently comprises16 NRAs; countries joined the Working Group voluntarily with the commitment to advance towards strengthening the Regulatory Capacity on Medical Devices through Regional exchange of information, joint projects, and training strategies towards the harmonization of regulatory requirements. This group is led by CECMED, the Cuban NRA (PAHO, 2018b): Specialist from regional reference authorities are a collection of experts in NRA acting as PAHO advisory experts of the system for evaluation of national reference regulatory authorities; 26 ARNs have so far been evaluated. Center for the State Control of Drugs and Medical Devices (CECMED) is working with PAHO and the Ministry of Health to strengthen the Nicaraguan National Regulatory Authority of Drugs as part of the technology transfer project for production of biologicals and immuno- biologicals between the governments of Russia and Nicaragua (PAHO,2018a) The regional reference NRA group is coordinated by one of its members for a period of two years. In the meetings different international forums and meetings that take place during the year, most current topics and initiatives, criteria, concerns and position are discussed. After the discussion process they try to adopt joint position responding to regional concerns. These actions are of particular importance during the international consultation process on the strengthening of the regulatory systems developed by WHO since October 2014 aimed at reaching a Global Benchmarking Tool (GBT) for evaluation of national regulatory system of medical products. The World Health Organization began assessing regulatory systems in 1997 using a set of indicators, designed to evaluate regulatory programmes for vaccines. Since that time, a number of tools and revisions were introduced. In 2014, work started on the development of a unified tool for evaluation of medicines and vaccines regulatory programmes following a mapping of existing tools in use within and external to WHO (WHO, 2018). For this, tools already applied by the organization, the tool used by the Pan American Health Organization for the evaluation and designation of Regional Reference Authorities, the standards established by the ISO standards, among others, were taken into account. The final objective was to have only one tool that replaces all tools previously used by WHO, representing the first truly ‘global’ tool for benchmarking regulatory systems. Recently, WHO has published a new document (Revision VI) that has taken into consideration inputs received from two international consultations with Member States in 2015, a public consultation in early 2018 and a series of meetings involving experts from regulatory authorities from different parts of the world. The work of the Americas region, (represented by P AHO), was significant, particularly as the region that already had a tool and an evaluation process with 8 years of experience. This last document contains a large part of recommendations and criteria, made by the NRAs and has incorporated indicators and measures criteria of the evaluation tool used in the process developed in the Americas. The document would be used to evaluate and publicly designate WHO-listed authorities (WLAs), which have objectively been documented to perform at high maturity levels in 2019. Conclusion The process of evaluation and certification of Regional Reference National Regulatory Authorities in the Americas completes 9 years of establishment in 2019. During these years, the initiative has succeeded in building capacities in the drug regulatory agency in the region strengthening their medicines regulatory systems,. An example is the process of strengthening the Nicaraguan National Drug Regulatory Authority as part of the technology transfer project for the production of biological and inmuno-biologicals, implemented by the governments of Russia and Nicaragua and the process of development of regional ecosystems, to evaluate the regulatory capacity on medical devices. The joint work of the regional reference authorities can be an example of the real implementation of science diplomacy based on the international collaboration of the authorities involved; showing their engagement in value- based international partnerships. This alliance adds values to national medicines programmes and other Ministries of Health missions. The development of joint capacity-building programmes enables taking advantage of the strengths of each member of the group of authorities for the benefit of their regional counterparts while sharing responsibilities and expenditures with maximized results to assure safety, efficacy and quality of medicines. Effective regulatory systems are an essential component of health systems and contribute to desired public health outcomes.

Sign in to recut, update, or save this card.